Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 18,709 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic Disease Clear all
Completed Phase 3 Interventional Results available

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

NCT05378672
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
Up to 5 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

NCT01194245
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Escondido, California • La Jolla, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 4 Interventional Results available

Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity

NCT04614545
View directory record Official record
Conditions
Obesity
Interventions
Phentermine 37.5 Mg, Dietary program, Exercise program
Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 12, 2026, 8:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers for Noninvasive Assessment of Human Hydration

NCT01507129
View directory record Official record
Conditions
Dehydration
Interventions
Not listed
Lead sponsor
Gaia Medical Institute
Industry
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PrOtein and WEight Loss in teenageRs

NCT02079831
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Energy Restriction, Higher protein, Lower Protein
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
12 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults

NCT04663139
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Xla1, Placebo
Drug
Lead sponsor
YSOPIA Bioscience
Industry
Eligibility
19 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 12, 2026, 8:24 PM EDT
Recruiting No phase listed Observational

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

NCT06401577
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Dexcom Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 1Phase 2 Interventional

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

NCT03678259
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
124I-p5+14 Injection
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

NCT00001596
View directory record Official record
Conditions
Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
William Gahl, M.D.
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

NCT02139046
View directory record Official record
Conditions
Gout
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
192
States / cities
Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

NCT00839527
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo to match albiglutide, albiglutide, metformin, glimepiride, pioglitazone, placebo to match pioglitazone
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
321
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 257 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Long-Term Study of Nitisinone to Treat Alkaptonuria

NCT00107783
View directory record Official record
Conditions
Alkaptonuria
Interventions
Nitisinone (NTBC)
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

NCT02537470
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
Biphasic Remogliflozin Etabonate, Placebo
Drug · Other
Lead sponsor
BHV Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Not applicable Interventional

Resilient, Empowered, Active Living: REAL Diabetes Study

NCT02214641
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Resilient, Empowered, Active Living with Diabetes, Information Control
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 30 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 12, 2026, 8:24 PM EDT
Not listed Phase 2Phase 3 Interventional

An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III

NCT06614894
View directory record Official record
Conditions
Sanfilippo Syndrome, MPS3
Interventions
Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day
Drug
Lead sponsor
Ozlem Goker-Alpan
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Fructose Corn Syrup

NCT02018237
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Obesity
Interventions
High fructose corn syrup diet, Standard diet (low in high fructose corn syrup)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 12, 2026, 8:24 PM EDT
Not listed Not applicable Interventional

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness

NCT03627377
View directory record Official record
Conditions
Schizophrenia, Obesity, Diabetes, Lifestyle Risk Reduction, Serious Mental Illness
Interventions
Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

WeCareAdvisor Study for Caregivers of People Living With Dementia

NCT05012410
View directory record Official record
Conditions
Dementia, Caregiver Burnout, Caregiver Stress Syndrome, Alzheimer Disease, Frontotemporal Dementia, Vascular Dementia, Dementia With Lewy Bodies
Interventions
Immediate treatment group with High-Intensity Prompts, Immediate treatment group with Low-Intensity Prompts, Waitlist Control after three months with High-Intensity Prompts, Waitlist Control after three months with Low-Intensity Prompts
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
21 Years and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 4 Interventional Results available

Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)

NCT00726713
View directory record Official record
Conditions
Type 2 Diabetic Peripheral Neuropathy (DPN)
Interventions
Metanx (a medical food), Metanx placebo
Other
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
25 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 3 Interventional

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

NCT00070382
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

STEP AND GO: A Study of Technology-based Exercise Promotion

NCT01953224
View directory record Official record
Conditions
Cardiovascular Disease, Obesity, Cancer, Diabetes
Interventions
Game-based intervention, Smartphone
Behavioral · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 12, 2026, 8:24 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Role of Estrogen in Adipocyte Remodeling Following Surgical Menopause

NCT03631680
View directory record Official record
Conditions
Menopause Surgical, Estrogen Deficiency, Adiposity
Interventions
Bilateral Oophorectomy Surgery
Procedure
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Steps Ahead, Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population

NCT01584596
View directory record Official record
Conditions
Obesity
Interventions
Adapted Dietary Guidelines, Adapted Physical Activity Guidelines
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 64 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 12, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Stem Cell Therapy for Chronic Kidney Disease

NCT04869761
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 12, 2026, 8:24 PM EDT